Does the microenvironment influence the cell types of origin for prostate cancer?

Genes and Development

Volumn 27, Issue 14, 2013, Pages 1539-1544

  Goldstein, Andrew S ^a,b   Witte, Owen N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell of origin; Inflammation; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; GROWTH FACTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; TRANSCRIPTIOR FACTOR NKX3.1; UNCLASSIFIED DRUG;

ANTIANDROGEN THERAPY; BASAL CELL; CANCER CELL; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DEDIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TYPE; EDITORIAL; EPITHELIUM CELL; GENETIC ENGINEERING; HUMAN; INFLAMMATION; MESENCHYME CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

CELL OF ORIGIN; INFLAMMATION; PROSTATE CANCER;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR MICROENVIRONMENT; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; EPITHELIAL CELLS; HUMANS; INFLAMMATION; MALE; MICE; PROSTATIC NEOPLASMS;

EID: 84880428498     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.222380.113     Document Type: Editorial

References (64)

1. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM. 2003. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63: 3886-3890.
2. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. 2010. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
3. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, et al. 2002. Projection of an immunological self shadow within the thymus by the aire protein. Science 298: 1395-1401.
4. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, et al. 2012. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44: 685-689.
5. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. 2011. The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
6. Berquam-Vrieze KE, Nannapaneni K, Brett BT, Holmfeldt L, Ma J, Zagorodna O, Jenkins NA, Copeland NG, Meyerholz DK, Knudson CM, et al. 2011. Cell of origin strongly influences genetic selection in a mouse model of T-ALL. Blood 118: 4646-4656.
7. Birbach A, Eisenbarth D, Kozakowski N, Ladenhauf E, Schmidt- Supprian M, Schmid JA. 2011. Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia 13: 692-703.
8. Cai H, Babic I, Wei X, Huang J, Witte ON. 2011. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 71: 862-872.
9. Choi N, Zhang B, Zhang L, Ittmann M, Xin L. 2012. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 21: 253-265.
10. Cunha GR, Lung B. 1978. The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool 205: 181-193.
11. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. 1999. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 155: 1985-1992.
12. De Marzo AM, Nakai Y, Nelson WG. 2007a. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol 25: 398-400.
13. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. 2007b. Inflammation in prostate carcinogenesis. Natl Rev 7: 256-269.
14. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, et al. 2011. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470: 269-273.
15. Feldman BJ, Feldman D. 2001. The development of androgenin-dependent prostate cancer. Natl Rev 1: 34-45.
16. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS 2nd, Revelo MP, Bhowmick NA, Hayward SW. 2011. Altered TGF-b signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 71: 1272-1281.
17. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, Ellisman MH, Verma IM. 2012. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338: 1080-1084.
18. Fuchs E, Horsley V. 2011. Ferreting out stem cells from their niches. Nat Cell Biol 13: 513-518.
19. Garber K. 2010. A tale of two cells: Discovering the origin of prostate cancer. J Natl Cancer Inst 102: 1528-1529, 1535.
20. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. 2010. Identification of a cell of origin for human prostate cancer. Science 329: 568-571.
21. Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang H, Reiter RE, Huang J, Witte ON. 2011. Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc 6: 656-667.
22. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243.
23. Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, Svensson RU, Henry MD, Wang HH, Ratliff TL. 2011. An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate 71: 1139-1150.
24. Hellerstedt BA, Pienta KJ. 2002. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154-179.
25. Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L. 2009. An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest 119: 2031-2041.
26. Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, Calcinotto A, Freschi M, Mondino A, Galli R, et al. 2013. Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. OncoImmunology 2: e24520.
27. Kazma R, Mefford JA, Cheng I, Plummer SJ, Levin AM, Rybicki BA, Casey G, Witte JS. 2012. Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS ONE 7: e51680.
28. Klotz L. 2013. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endo Diab Obes 20: 204-209.
29. Ko SB, Azuma S, Yokoyama Y, Yamamoto A, Kyokane K, Niida S, Ishiguro H, Ko MS. 2013. Inflammation increases cells expressing ZSCAN4 and progenitor-cell markers in the adult pancreas. Am J Physiol Gastrointest Liver Physiol 304: G1103-G1116.
30. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. 2008. Recurrent gene fusions in prostate cancer. Natl Rev 8: 497-511.
31. Lakso M, Sauer B, Mosinger B Jr, Lee EJ, Manning RW, Yu SH, Mulder KL, Westphal H. 1992. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci 89: 6232-6236.
32. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. 2010. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci 107: 2610-2615.
33. Liao CP, Adisetiyo H, Liang M, Roy-Burman P. 2010a. Cancerassociated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70: 7294-7303.
34. Liao CP, Adisetiyo H, Liang M, Roy-Burman P. 2010b. Cancer stem cells and microenvironment in prostate cancer progression. Horm Cancer 1: 297-305.
35. Liu K, Jiang M, Lu Y, Chen H, Sun J, Wu S, Ku WY, Nakagawa H, Kita Y, Natsugoe S, et al. 2013. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 12: 304-315.
36. Logothetis CJ, Lin SH. 2005. Osteoblasts in prostate cancer metastasis to bone. Natl Rev 5: 21-28.
37. Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM. 2013. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am J Pathol 182: 975-991.
38. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. 2009. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326: 1230.
39. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON. 2007. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12: 572-585.
40. Mimeault M, Batra SK. 2013. Development of animal models underlining mechanistic connections between prostate inflammation and cancer. J Clin Oncol 4: 4-13.
41. high stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69: 8555-8562.
42. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H. 2012. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72: 1878-1889.
43. Ousset M, Van Keymeulen A, Bouvencourt G, Sharma N, Achouri Y, Simons BD, Blanpain C. 2012. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat Cell Biol 14: 1131-1138.
44. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
45. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. 2012. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18: 1359-1368.
46. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
47. Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L, Australian Prostate Cancer Bioresource, Collins AT, Maitland NJ, Risbridger GP. 2012. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells 30: 1087-1096.
48. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
49. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, et al. 2008. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13: 519-528.
50. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM. 2003. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 162: 1529-1537.
51. Visvader JE. 2011. Cells of origin in cancer. Nature 469: 314-322.
52. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR. 2000. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 60: 6008-6017.
53. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, et al. 2003. Prostatespecific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209-221.
54. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. 2006. Pten deletion leads to the expansion of a prostatic stem/ progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci 103: 1480-1485.
55. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.
56. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, et al. 2012. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72: 4765-4776.
57. Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, Shen MM. 2013. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 15: 274-283.
58. Xin L, Ide H, Kim Y, Dubey P, Witte ON. 2003. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci 100: 11896-11903.
59. Xin L, Lawson DA, Witte ON. 2005. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci 102: 6942-6947.
60. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. 2006. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci 103: 7789-7794.
61. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, Zielenska M, Squire JA. 2006. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169: 128-137.
62. Zong Y, Goldstein AS. 2013. Adaptation or selection-mechanisms of castration-resistant prostate cancer. Nat Rev Urol 10: 90-98.
63. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. 2009. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci 106: 12465-12470.
64. Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein JI, Chada KK, Witte ON. 2012. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci 109: E3395-E3404.